NCT01085344View on ClinicalTrials.gov

Canadian Hemophilia Prophylaxis Study

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 26, 1997

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2014

Conditions
Severe Hemophilia A
Interventions
BIOLOGICAL

Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)

escalating dose prophylaxis

BIOLOGICAL

Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)

escalating dose

Trial Locations (1)

M5G 1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT01085344 - Canadian Hemophilia Prophylaxis Study | Biotech Hunter | Biotech Hunter